| scholarly article | Q13442814 |
| P50 | author | Helio S Sader | Q63144492 |
| Michael J Rybak | Q106082725 | ||
| Ronald N Jones | Q120908182 | ||
| P2093 | author name string | Kerri L Rossi | |
| Steve N Leonard | |||
| Chrissy M Cheung | |||
| P2860 | cites work | Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections | Q24652784 |
| Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia | Q28145964 | ||
| Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know | Q31704853 | ||
| Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options | Q32058531 | ||
| Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus | Q33977356 | ||
| Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus | Q34073407 | ||
| Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis | Q34885043 | ||
| Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia | Q35023343 | ||
| Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| Reference group choice and antibiotic resistance outcomes | Q35880537 | ||
| Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). | Q36306687 | ||
| Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains | Q36328966 | ||
| The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 | ||
| Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. | Q37058087 | ||
| Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides | Q39465279 | ||
| Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus | Q39656261 | ||
| Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Historical yearly usage of vancomycin. | Q42743595 | ||
| A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides | Q42912582 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital | Q43552304 | ||
| Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin | Q45255740 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital | Q46802703 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment | Q46851716 | ||
| Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan | Q74823194 | ||
| Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus | Q80363319 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vancomycin | Q424027 |
| Staphylococcus aureus | Q188121 | ||
| P304 | page(s) | 2950-2954 | |
| P577 | publication date | 2008-07-16 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). | |
| P478 | volume | 46 |
| Q41999444 | Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations |
| Q41807543 | Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies |
| Q46708063 | Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011. |
| Q28550691 | Antibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse Model |
| Q33826253 | Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008 |
| Q40098505 | Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus. |
| Q51738217 | Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA. |
| Q37124131 | Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection |
| Q35066896 | Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au |
| Q37581376 | Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus |
| Q38425879 | Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus |
| Q37849391 | Clinical management of Staphylococcus aureus bacteraemia |
| Q35819831 | Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units |
| Q37465197 | Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management |
| Q42090736 | Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus |
| Q42169334 | Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method |
| Q35959546 | Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin |
| Q38123255 | Current and prospective treatments for multidrug-resistant gram-positive infections. |
| Q26853465 | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci |
| Q38615330 | Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections |
| Q33613735 | Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. |
| Q42773139 | Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods |
| Q45290718 | Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus |
| Q41907664 | Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro |
| Q41429045 | Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods |
| Q36265781 | Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent |
| Q41016957 | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia |
| Q98164449 | Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis |
| Q37717901 | Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance |
| Q36692468 | Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance |
| Q35848781 | High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. |
| Q40261278 | Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q36999966 | Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves |
| Q42738202 | In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates |
| Q42130598 | In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types |
| Q41387835 | Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center |
| Q36856946 | Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? |
| Q40600332 | Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. |
| Q38171759 | Methicillin-resistant Staphylococcus aureus: an evolving pathogen |
| Q40003834 | Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. |
| Q41877894 | Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates |
| Q42943425 | Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus |
| Q36644689 | Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter? |
| Q36037687 | Predicting risk for death from MRSA bacteremia |
| Q36636699 | Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients |
| Q37333104 | Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. |
| Q34290139 | Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). |
| Q36501398 | Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York Hospital |
| Q50420166 | Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. |
| Q34998629 | Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China |
| Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
| Q27011138 | Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections |
| Q41943324 | Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains |
| Q55014868 | Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility. |
| Q41031199 | Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmatio |
| Q28481497 | Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model |
| Q26796560 | Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates |
| Q37809666 | Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates |
| Q37776832 | The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains |
| Q27015976 | Treatment of Gram-positive infections in critically ill patients |
| Q42914487 | Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria |
| Q54392892 | Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? |
| Q43117809 | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years |
| Q35064413 | Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey |
| Q33945397 | Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. |
| Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
| Q42153532 | Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates |
| Q43094503 | Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. |
Search more.